(NASDAQ: EOLS) Evolus's forecast annual revenue growth rate of 15.57% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.54%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.89%.
Evolus's revenue in 2026 is $301,791,000.On average, 9 Wall Street analysts forecast EOLS's revenue for 2026 to be $22,196,343,825, with the lowest EOLS revenue forecast at $21,187,449,039, and the highest EOLS revenue forecast at $23,026,113,687. On average, 9 Wall Street analysts forecast EOLS's revenue for 2027 to be $26,041,602,735, with the lowest EOLS revenue forecast at $24,079,131,156, and the highest EOLS revenue forecast at $27,589,847,931.
In 2028, EOLS is forecast to generate $30,834,511,513 in revenue, with the lowest revenue forecast at $27,847,998,555 and the highest revenue forecast at $33,467,384,458.